Technology
Health
Medical

Nevro

$62.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.29 (0.47%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Nevro and other stocks, options, ETFs, and crypto commission-free!

About

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. Read More It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Employees
804
Headquarters
Redwood City, California
Founded
2006
Market Cap
1.88B
Price-Earnings Ratio
โ€”
Dividend Yield
0.00
Average Volume
699.57K
High Today
$62.77
Low Today
$60.64
Open Price
$61.87
Volume
494.94K
52 Week High
$94.34
52 Week Low
$34.75

Collections

Technology
Health
Medical
Medical Devices
2014 IPO
US
North America

News

Guru FocusMar 21

Nevro and Avanos Leading Charge to Opioid-Free Pain Treatments

Nevro Corp. (NVRO) is among a host of public and private companies marketing or developing medical devices to treat pain. These companies are striving to develop alternatives to opioids for the some 50 million people in the U.S. that experience chronic pain daily or almost daily. The opioid crisis has been well documented. Every day, more than 130 people in the country die after overdosing on opioids, according to the National Institute for Drug Abuse. These include prescription pain medications, heroin an...

49
PR NewswireMar 21

Why 2019 U.S. Medical Device Market Is Expected to Exceed Last Year Revenues

PALM BEACH, Florida, March 21, 2019 /PRNewswire/ -- A recent article in a medical device industry periodical, INN, said that: "2018 has been an important year for the medical device industry as M&A, technology and regulatory catalysts have impacted the market.

1
MarketWatchMar 21

Nevro Corp. Stock Quote (U.S.: NYSE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro (NVRO) and NuVasive (NUVA). Nevro (NVRO) Morgan ...[...] Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Nevro (NVRO) delivered earnings and revenue surprises of -88.24% and 0.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock? Nevro Co...

32

Earnings

-$0.59
-$0.44
-$0.29
-$0.14
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
โ€”
Actual
Expected May 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.